Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): A randomized, controlled, double-blind study

Journal of Psychiatric Practice

Volumn 18, Issue 4, 2012, Pages 269-280

  Španiel, Filip ^a   Hrdlička, Jan ^b   Novák, Tomáš ^a   Kožený, Jiří ^a   Höschl, Cyril ^a   Mohr, Pavel ^a   Motlová, Lucie Bankovská ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

antipsychotic medication; hospitalizations; information technology; psychotic disorders; relapse prevention; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFORMATION TECHNOLOGY; INFORMATION TECHNOLOGY AIDED PROGRAM OF RELAPSE PREVENTION IN SCHIZOPHRENIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; EARLY DIAGNOSIS; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT READMISSION; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RECURRENCE; SCHIZOPHRENIA; SURVIVAL ANALYSIS; TELEMEDICINE;

EID: 84863968630     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000416017.45591.c1     Document Type: Article

References (30)

1. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16. (Pubitemid 36752981)
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
3. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the patho-physiology of schizophrenia. J Clin Psychiatry 1996;57: 5-9. (Pubitemid 26327751)
4. Shepherd M, Watt D, Falloon I, et al. The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 1989;15:1-46. (Pubitemid 19234086)
5. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24:75-85. (Pubitemid 28128490)
6. Cahn W, Rais M, Stigter FP, et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009;19:147-51.
7. Lieberman JA, Tollefson GD, Charles C, et al. Anti -psychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-70. (Pubitemid 40471685)
8. McGlashan TH. Is active psychosis neurotoxic? Schizophr Bull 2006;32:609-13.
9. Seok Jeong B, Kwon JS, Yoon Kim S, et al. Functional imaging evidence of the relationship between recurrent psychotic episodes and neurodegenerative course in schizophrenia. Psychiatry Res 2005;139:219-28. (Pubitemid 41116665)
10. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study. Neuropsychopharmacology 2007;32:2057-66. (Pubitemid 47417696)
11. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-45. (Pubitemid 26277886)
12. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93. (Pubitemid 38828535)
13. McKusick D, Mark TL, King E, et al. Spending for mental health and substance abuse treatment, 1996. Health Aff (Millwood) 1998;17:147-57. (Pubitemid 128465528)
14. Birchwood M, Spencer E. Early intervention in psychotic relapse. Clin Psychol Rev 2001;21:1211-26. (Pubitemid 33033124)
15. Herz MI, Lamberti JS, Mintz J, et al. A program for relapse prevention in schizophrenia: A controlled study. Arch Gen Psychiatry 2000;57:277-83. (Pubitemid 30140437)
16. Spaniel F, Vohlidka P, Hrdlicka J, et al. ITAREPS: Information technology aided relapse prevention programme in schizophrenia. Schizophr Res 2008;98:312-7. (Pubitemid 350235892)
17. Spaniel F, Vohlidka P, Kozeny J, et al. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: An extension of a mirror-design follow-up. Int J Clin Pract 2008;62:1943-6.
18. World Health Organization (WHO). International statistical classification of diseases and related health problems, 10th edition (ICD-10) Geneva, Switzerland: WHO; 1992.
19. Guy W. ECDEU Assessment manual for psychopharma-cology. Washington, DC: U.S. Public Health Service, U.S. Government Printing Office; 976:534-7.
20. Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy; 18-month follow-up. Br J Psychiatry 1998;172:413-9. (Pubitemid 28204550)
21. American Psychiatric Association. Global Assessment of Functioning scale. In: Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000:32-4.
22. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346: 16-22 (Pubitemid 34438915)
23. Birchwood M, Smith J, Macmillan F et al. Predicting relapse in schizophrenia: The development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med 1989;19:649-56. (Pubitemid 19243711)
24. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res 2007;95:19-29. (Pubitemid 47313652)
25. Marder SR, Van PT, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41: 1025-9. (Pubitemid 14017411)
26. Subotnik KL, Nuechterlein KH. Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 1988;97:405-12. (Pubitemid 18266364)
27. Geddes J, Mercer G, Frith CD, et al. Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. Br J Psychiatry 1994;165:664-8. (Pubitemid 24333523)
28. Grossman LS, Harrow M, Rosen C, et al. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv 2006;57: 844-50. (Pubitemid 43846297)
29. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsy -chotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-62.
30. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)